Researcher To Test First-In-Class Compound For Neuroprotection, In The Hopes Of Stopping MS Disease Progression
Wednesday, November 20, 2013 - 11:00
in Health & Medicine
A $500,000 drug development grant from the National Multiple Sclerosis Society (NMSS) was awarded to a partnership between a multiple sclerosis research team at the Icahn School of Medicine at Mount Sinai and Karyopharm Therapeutics Inc., a clinical stage pharmaceutical company.